Salarius Pharmaceuticals and Nationwide Children’s Hospital

HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new drugs for patients with childhood cancer, solid tumors and other cancers, and Nationwide Children’s Hospital announced today that an abstract has been accepted by the American Association for Cancer Research (AACR) for poster presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The abstract highlights research into the ability of Salarius’ lead drug candidate, seclidemstat (SP-2577), to target FET rearranged sarcomas through the inhibition of the non-enzymatic function (ie, scaffolding function) of the LSD1 enzyme. The conference will take place virtually from October 7-10, 2021.

The title and authors of the abstract from Salarius and Nationwide Children’s Hospital are as follows:

Summary title: Targeting the function of LSD1 protein scaffold in FET rearranged sarcomas with SP-2577

Summary authors: Galen Rask, Research Assistant, National Children’s Hospital; Emily Theisen, Ph.D., principal investigator, The Center for Childhood Cancer and Blood Diseases at the Abigail Wexner Research Institute, Nationwide Children’s Hospital; Aundrietta Duncan, Ph.D., director of non-clinical development, Salarius Pharmaceuticals; Daniela Santiesteban, Ph.D., director of business development, Salarius Pharmaceuticals

“Inhibition of LSD1 is a growing area of ​​cancer drug development research, and we are pleased that research underscoring our decision to expand seclidemstat’s clinical program to FET sarcomas will be the subject of a poster presentation at the AACR -NCI-EORTC 2021,” said David Arthur, CEO of Salarius Pharmaceuticals. “We believe that seclidemstat targets both the enzymatic activity and non-enzymatic activities of LSD1 and provides a differentiated mechanism of action that more potently inhibits the cancer-promoting properties of LSD1 and could provide differentiated therapeutic activity in different cancers.”

dr. Theisen stated: “We are excited to participate in research on the activity of seclidemstat in FET-rearranged sarcomas. Malignancies caused by gene expression due to epigenome dysregulation are therapeutically targeted, and the inhibition of LSD1 is a promising area of ​​research. We look forward to future developments that bring new therapies to patients and their families.”

Salarius is conducting a Phase 1/2 clinical trial evaluating patients with myxoid liposarcoma and other FET-rearranged sarcomas treated with seclidemstat as monotherapy. The same study is also evaluating seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide as a potential second- and third-line therapy for Ewing’s sarcoma. More recently, Salarius expanded into hematologic cancers, with the MD Anderson Cancer Center activating an investigator-initiated phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine.

The titles of all abstracts accepted for presentation at the conference are currently available on the AACR website at and cancer therapeutics/. The full abstracts, including the dates and times of presentations, are scheduled for release on October 7, 2021 at 9:00 a.m. ET.

About the national children’s hospital

Named in the Top 10 Honor Roll on U.S. News & World Report’s 2021-22 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest nonprofit freestanding pediatric health care systems offering wellness, preventive, diagnostic, treatment provide and rehabilitation care for infants, children and adolescents, as well as adult patients with congenital disease. Nationwide Children’s has more than 13,000 employees who provide state-of-the-art pediatric care during more than 1.6 million patient visits per year. Home to the Ohio State University College of Medicine’s Department of Pediatrics, National Pediatricians educate the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health funded freestanding pediatric research facilities. More information is available at

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ lead candidate, seclidemstat, is under investigation as a potential treatment for childhood cancer, sarcomas and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and is selecting additional sarcomas that have a similar biology to Ewing sarcoma, also known as Ewing-related or FET rearranged sarcomas. Seclidemstat has received the Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the US Food and Drug Administration. Salarius is also developing seclidemstat for several cancers of high unmet medical need, with a second phase 1/2 clinical trial in hematologic cancers. Salarius has received funding from the National Pediatric Cancer Foundation to advance the clinical program for Ewing sarcoma and also received a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, visit or follow Salarius on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. These forward-looking statements can be identified by terms such as “potential,” “progress,” “design,” “estimate,” “continue,” “will,” “striving,” “may,” “believe,” “plan ‘. ”, “allow”, “expect”, “intend”, “target”, “offer”, “can”, “position”, “project”, “develop”, “look ahead” and similar terms or expressions or the negative of it. Examples of such statements include, but are not limited to, statements regarding the following: Salarius’ growth strategy; the value of seclidemstat as a potential treatment for Ewing sarcoma, FET rearranged sarcomas and other cancers; the ability of seclidemstat to target and inhibit LSD1; the differential therapeutic activity of seclidemstat in various cancers, including solid tumors; Salarius develops seclidemstat for various cancers with high unmet medical need; bring new therapies to market; and Salarius’ plans to initiate additional clinical trials. Salarius may not actually realize the plans, execute its intentions or meet the expectations or objectives stated in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the adequacy of Salarius’ capital resources; Salarius’ ability and need to raise additional capital to meet Salarius’ operational needs and achieve its business objectives and strategy; Salarius’ ability to project future capital needs and cash use and their timing and accuracy; Salarius’ ability to access the remaining funding available under the CPRIT grant; future clinical trial results and impact of the results on Salarius; that the results of studies and clinical trials may not be predictive of future results of clinical trials; the adequacy of Salarius’ intellectual property protection; risks associated with drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions and legal or contractual restrictions that may affect Salarius’ ability to raise additional capital; the possibility of unexpected expenses or other uses of Salarius’ funds; risks associated with the COVID-19 outbreak; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those discussed in Salarius’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Salarius’ Annual Report on Form 10-K for the year ended December 31, 2020. The forward-looking statements in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of that date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or conditions that exist after the date they are made.

Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA (Investors)
(212) 375-2664

Johanna Bennett (media)
(212) 375-2686

Comments are closed.